Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 5
Submit an article Journal homepage
587
Views
18
CrossRef citations to date
0
Altmetric
Original Research

First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China

Zhiguang Yanga School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, China;b Department of Healthcare Reform, National Health Commission of the People’s Republic of China, Beijing, ChinaView further author information
,
Yumei Zhua School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaORCID Iconhttps://orcid.org/0000-0002-5798-2901View further author information
ORCID Icon,
Guiyuan Xianga School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaView further author information
,
Tiantian Huaa School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaView further author information
,
Jun Nic Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical University, Fujian, China;d Department of Rehabilitation Medicine, The Affiliated Hospital of Nantong University, Nantong, ChinaView further author information
,
Jie Zhaoe Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Yun Lua School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaView further author information
,
Yingyu Wua School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaView further author information
&
Feng Changa School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 1061-1067 | Received 14 Oct 2020, Accepted 03 Mar 2021, Published online: 19 Mar 2021

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Shuo Kang & Huanlong Liu. (2023) Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-8.
Read now
Fangjian Shang, Boyuan Zhang & Shuo Kang. (2023) Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research 23:3, pages 337-343.
Read now

Articles from other publishers (16)

Changjin Wu, Wentan Li, Hongyu Tao, Xiyan Zhang, Yu Xin, Ruomeng Song, Kaige Wang, Ling Zuo, Yuanyi Cai, Huazhang Wu & Wen Hui. (2023) Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview. Critical Reviews in Oncology/Hematology, pages 104195.
Crossref
Xueyan Liang, Xiaoyu Chen, Huijuan Li & Yan Li. (2023) Cost–effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer. Immunotherapy.
Crossref
Yingyao Chen, Hengjin Dong, Yan Wei, Yi Yang, Jian Ming & Hao Yu. (2023) Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy. BMJ, pages e069963.
Crossref
Hao Wang, Yunchun Long, Yuan Xu, Li Liao & Yujie Zhou. (2023) Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer. Frontiers in Public Health 11.
Crossref
Xi Chen, Mingye Zhao & Lei Tian. (2023) Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis. Frontiers in Pharmacology 14.
Crossref
Gengwei Huo, Wenjie Liu, Shuo Kang & Peng Chen. (2023) Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. Frontiers in Pharmacology 14.
Crossref
Lan-Lan Pang, Jia-Di Gan, Yi-Hua Huang, Jun Liao, Wei-Tao Zhuang, Wael-Abdullah-Sultan Ali, Shao-Dong Hong, Li Zhang & Wen-Feng Fang. (2023) Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer 23:1.
Crossref
Wei Li & Li Wan. (2022) Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China. Frontiers in Public Health 10.
Crossref
Yalei Wen, Yingjie Zhu, Caishi Zhang, Xiao Yang, Yuchen Gao, Mei Li, Hongyan Yang, Tongzheng Liu & Hui Tang. (2022) Chronic inflammation, cancer development and immunotherapy. Frontiers in Pharmacology 13.
Crossref
Zhiwei Zheng, Huide Zhu, Ling Fang & Hongfu Cai. (2022) Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. Frontiers in Pharmacology 13.
Crossref
Yingkai Chen, Shizhou Kang & Ming Yan. (2022) Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis. Pharmacology Research & Perspectives 10:3.
Crossref
Shuo Kang, Xinchen Wang, Yue Zhang, Boyuan Zhang, Fangjian Shang & Wei Guo. (2022) First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis. Frontiers in Oncology 11.
Crossref
Chen Zhu, Xiao-xuan Xing, Bin Wu, Gang Liang, Gang Han, Cai-xia Lin & Hong-mei Fang. (2021) Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. Frontiers in Pharmacology 12.
Crossref
Guiyuan Xiang, Lingna Gu, Xuan Chen, Fan Wang, Bohua Chen, Jie Zhao, Yun Lu, Feng Chang & Yumei Zhu. (2021) Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China. Frontiers in Public Health 9.
Crossref
Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan & Chongqing Tan. (2021) Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Advances in Therapy 38:7, pages 3962-3972.
Crossref
Guoqiang Liu, Shuo Kang, Xinchen Wang & Fangjian Shang. (2021) Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. Frontiers in Oncology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.